Aug 24, 2025, 01:32
Minhua Chu: Zelgen Biopharma’s ZGGS34 Gets FDA Approval for Solid Tumor Study
Minhua Chu, Managing Partner at TransitionValue Partner, shared on X:
“Zelgen Biopharma’s investigational product, ZGGS34 (MUC17/CD3/CD28) injection, has received approval from the FDA for its clinical trial application to treat advanced solid tumors.
ZGGS34 is a trispecific antibody drug developed by the company and its subsidiary, Gensun Biopharma Inc., through its bispecific/multispecific antibody development platform, belonging to the class of trispecific T-cell engager (TriTE) antibody molecules.”
More posts featuring Minhua Chu on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 24, 2025, 01:32
Aug 23, 2025, 22:57
Aug 23, 2025, 22:35
Aug 23, 2025, 22:10
Aug 23, 2025, 21:42
Aug 23, 2025, 21:31
Aug 23, 2025, 20:55
Aug 23, 2025, 20:22